249 related articles for article (PubMed ID: 35630836)
1. Synthesis and Biochemical Evaluation of 8
Wu J; Feng B; Gao LX; Zhang C; Li J; Xiang DJ; Zang Y; Wang WL
Molecules; 2022 May; 27(10):. PubMed ID: 35630836
[TBL] [Abstract][Full Text] [Related]
2. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
[TBL] [Abstract][Full Text] [Related]
3. Binding and inhibitory effect of ravidasvir on 3CL
Bera K
J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
[TBL] [Abstract][Full Text] [Related]
4. Thiazole-based SARS-CoV-2 protease (COV M
Elsayed RW; Sabry MA; El-Subbagh HI; Bayoumi SM; El-Sayed SM
Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200121. PubMed ID: 35607750
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
[TBL] [Abstract][Full Text] [Related]
6. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
[TBL] [Abstract][Full Text] [Related]
7. Geraniin as a potential inhibitor of SARS-CoV-2 3CL
Yu WD; Jin QY; Zeng MS; Liu JY; Xu PP
Nat Prod Res; 2022 Dec; 36(23):6060-6063. PubMed ID: 35200071
[TBL] [Abstract][Full Text] [Related]
8. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
[TBL] [Abstract][Full Text] [Related]
9. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D
Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor.
Konno H; Onuma T; Nitanai I; Wakabayashi M; Yano S; Teruya K; Akaji K
Bioorg Med Chem Lett; 2017 Jun; 27(12):2746-2751. PubMed ID: 28454669
[TBL] [Abstract][Full Text] [Related]
14. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.
Liu H; Iketani S; Zask A; Khanizeman N; Bednarova E; Forouhar F; Fowler B; Hong SJ; Mohri H; Nair MS; Huang Y; Tay NES; Lee S; Karan C; Resnick SJ; Quinn C; Li W; Shion H; Xia X; Daniels JD; Bartolo-Cruz M; Farina M; Rajbhandari P; Jurtschenko C; Lauber MA; McDonald T; Stokes ME; Hurst BL; Rovis T; Chavez A; Ho DD; Stockwell BR
Nat Commun; 2022 Apr; 13(1):1891. PubMed ID: 35393402
[TBL] [Abstract][Full Text] [Related]
15. Ligand-based design, synthesis, computational insights, and
Elagawany M; Elmaaty AA; Mostafa A; Abo Shama NM; Santali EY; Elgendy B; Al-Karmalawy AA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2112-2132. PubMed ID: 35912578
[TBL] [Abstract][Full Text] [Related]
16. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
[TBL] [Abstract][Full Text] [Related]
18. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
[TBL] [Abstract][Full Text] [Related]
19. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
Meyer-Almes FJ
Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
Konno S; Thanigaimalai P; Yamamoto T; Nakada K; Kakiuchi R; Takayama K; Yamazaki Y; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Freire E; Hayashi Y
Bioorg Med Chem; 2013 Jan; 21(2):412-24. PubMed ID: 23245752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
